LabCom PHYTOMAR’INNOV – PHYTOMAR

The PHYTOMAR'INNOV Joint Laboratory aims at the sustainable creation of a laboratory of excellence for the eco-design of innovative active ingredients, composed of molecules derived from marine algal and plant resources, allowing the design of products for the prevention of infectious diseases, in particular viral and bacterial ones.
To date, there is no national laboratory of excellence specialising in the applications of marine algal and plant resources for the food supplement and/or antiviral and antimicrobial medical device markets. The PHYTOMAR'INNOV LabCom aims to become a visible reference in these fields. A voluntary policy of publications and dissemination of information on the innovations of LabCom PHYTOMAR'INNOV will serve this ambition.
The main objective, for the 54 months of this LabCom, will therefore be to develop anti-infectious active principles, composed of polyphenols, from marine algal and plant resources. These active ingredients, whose efficacy and mechanisms of action will have been demonstrated, could be used in the composition of formulations intended for the food supplement and medical device, antiviral and antimicrobial markets. In more detail, we will develop two solutions:
The first will be devoted to the development of an original combination of natural extracts rich in polyphenols for the prevention of coronavirus infection. The coronaviruses responsible for three epidemics of severe acute respiratory syndromes in humans over the last twenty years, Sars-CoVS in 2003, Mers-CoV in 2012 and finally Sars-Cov2 in 2019, will be the priority targets.
The second will be devoted to the development of an original combination of natural extracts rich in polyphenols for the prevention of bacterial infections. The bacterial strains that we will use in the project are widely encountered in various human pathologies of food, pulmonary or other origin. They are often multi-resistant to antibiotics and responsible for more or less serious infections. They are methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase- producing enterobacteria (EBLSE). Some species such as Escherichia coli or Klebsiella pneumoniae are particularly resistant to third generation cephalosporins (C3G) or carbapenems. We will also look at Pseudomonas aeruginosa, which is widespread in hospital-acquired infections, or Salmonella enterica serovar Typhimurium and Listeria monocytogenes, which are responsible for serious food- borne infections.